Certuity LLC Has $775,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Certuity LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 44.2% in the 4th quarter, Holdings Channel reports. The fund owned 8,395 shares of the biopharmaceutical company’s stock after acquiring an additional 2,574 shares during the quarter. Certuity LLC’s holdings in Gilead Sciences were worth $775,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. HHM Wealth Advisors LLC increased its position in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares in the last quarter. nVerses Capital LLC bought a new position in Gilead Sciences in the third quarter valued at $25,000. YANKCOM Partnership bought a new position in Gilead Sciences in the fourth quarter valued at $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences in the fourth quarter valued at $29,000. Finally, Valued Wealth Advisors LLC grew its position in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now directly owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 572,824 shares of company stock valued at $53,611,715 in the last ninety days. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Price Performance

GILD stock opened at $96.14 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $100.51. The firm has a market cap of $119.82 billion, a P/E ratio of 1,068.22, a P/E/G ratio of 1.25 and a beta of 0.18. The company’s 50-day moving average price is $93.07 and its two-hundred day moving average price is $86.99.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. On average, analysts anticipate that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on GILD shares. Morgan Stanley raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $87.00 to $113.00 in a research report on Friday, January 10th. Sanford C. Bernstein started coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target for the company. Barclays increased their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research note on Thursday, November 7th. Wells Fargo & Company raised their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Finally, Robert W. Baird raised their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $98.39.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.